Back to discover
Disease

Inflammatory skin and bowel disease, neonatal, 2

Late-stage therapeutic development

Also known as EGFR neonatal inflammatory skin and bowel disease, inflammatory skin and bowel disease, neonatal, type 2, neonatal inflammatory skin and bowel disease caused by mutation in EGFR, NISBD2.

24
Clinical trials
1
Associated genes
1
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 3 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
Clinical Milestones18View all 18
Results posted 2
Results expected 3
Recently completed 5
Other updates 5
+10 more in the activity timeline below
Activity timeline18

Clinical trials

12 sponsors · 1 new · 6 completed in the last 12 months (net -3)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

A Phase 3 Multicenter Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Upadacitinib With Open-Label Induction, Randomized, Double-Blind Maintenance and Open-Label Long-Term Extension in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis and Inadequate Response, Intolerance, or Medical Contraindications to Corticosteroids, Immunosuppressants, and/or Biologic Therapy

Phase 3 · Active, not recruiting · AbbVie

A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis

Phase 3 · Active, not recruiting · Hoffmann-La Roche

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis

Phase 3 · Active, not recruiting · AbbVie

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy

Phase 3 · Active, not recruiting · argenx

A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

Phase 3 · Active, not recruiting · Abivax S.A.

A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease

Phase 3 · Active, not recruiting · AbbVie
Recently completed

A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Ulcerative Colitis

Phase 3 · Completed · Alfasigma S.p.A.

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Patients With Moderate to Severe Atopic Dermatitis

Phase 3 · Completed · Guangdong Hengrui Pharmaceutical Co., Ltd

Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events

Phase 4 · Completed · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

A Multicenter, Phase 3, Open-Label Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age With Moderately to Severely Active Ulcerative Colitis

Phase 3 · Completed · Eli Lilly and Company

Efficacy of Fecal Microbiota Transplantation in Critically Ill ICU Patients With Gastrointestinal Dysfunction-induced Enteral Nutrition Intolerance: a Single-center, Non-blind, Exploratory Study

Phase 2/3 · Completed · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis

Phase 3 · Completed · Eli Lilly and Company

Associated genes

1 match

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

EGFR0.64

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Epidermal growth factor receptorvia EGFR0.64

Reference

Authoritative identity, definition & identifiers.

Synonyms

EGFR neonatal inflammatory skin and bowel disease, inflammatory skin and bowel disease, neonatal, type 2, neonatal inflammatory skin and bowel disease caused by mutation in EGFR, NISBD2

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.